» Articles » PMID: 22491251

PD-1 Protects Against Inflammation and Myocyte Damage in T Cell-mediated Myocarditis

Overview
Journal J Immunol
Date 2012 Apr 12
PMID 22491251
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

PD-1, a member of the CD28 family of immune regulatory molecules, is expressed on activated T cells, interacts with its ligands, PD-L1/B7-H1 and PD-L2/B7-DC, on other cells, and delivers inhibitory signals to the T cell. We studied the role of this pathway in modulating autoreactive T cell responses in two models of myocarditis. In a CD8(+) T cell-mediated adoptive transfer model, we found that compared with Pd1(+/+) CD8(+) T cells, Pd1(-/-) CD8(+) T cells cause enhanced disease, with increased inflammatory infiltrate, particularly rich in neutrophils. Additionally, we show enhanced proliferation in vivo and enhanced cytotoxic activity of PD-1-deficient T lymphocytes against myocardial endothelial cells in vitro. In experimental autoimmune myocarditis, a disease model dependent on CD4(+) T cells, we show that mice lacking PD-1 develop enhanced disease compared with wild-type mice. PD-1-deficient mice displayed increased inflammation, enhanced serum markers of myocardial damage, and an increased infiltration of inflammatory cells, including CD8(+) T cells. Together, these studies show that PD-1 plays an important role in limiting T cell responses in the heart.

Citing Articles

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.


Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model.

Schoenherr C, Pietzsch S, Barca C, Muller F, Bahr F, Kasten M Front Mol Med. 2025; 4():1487526.

PMID: 39834851 PMC: 11743445. DOI: 10.3389/fmmed.2024.1487526.


The Two Faces of Angiopoietin-Like Protein 2 in Cancer.

Horiguchi H, Kadomatsu T, Oike Y Cancer Sci. 2024; 116(3):592-599.

PMID: 39686837 PMC: 11875762. DOI: 10.1111/cas.16434.


Changes in tumor and cardiac metabolism upon immune checkpoint.

Leven A, Wagner N, Nienaber S, Messiha D, Tasdogan A, Ugurel S Basic Res Cardiol. 2024; 120(1):133-152.

PMID: 39658699 PMC: 11790718. DOI: 10.1007/s00395-024-01092-8.


Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.

Gao H, Chen Z, Yao Y, He Y, Hu X Front Oncol. 2024; 14:1453090.

PMID: 39634266 PMC: 11614734. DOI: 10.3389/fonc.2024.1453090.


References
1.
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

2.
Bedke T, Pretsch L, Karakhanova S, Enk A, Mahnke K . Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10. J Immunol. 2010; 184(10):5562-70. DOI: 10.4049/jimmunol.0902458. View

3.
Sonderegger I, Rohn T, Kurrer M, Iezzi G, Zou Y, Kastelein R . Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol. 2006; 36(11):2849-56. DOI: 10.1002/eji.200636484. View

4.
Topalian S, Weiner G, Pardoll D . Cancer immunotherapy comes of age. J Clin Oncol. 2011; 29(36):4828-36. PMC: 3255990. DOI: 10.1200/JCO.2011.38.0899. View

5.
Sharpe A, Freeman G . The B7-CD28 superfamily. Nat Rev Immunol. 2002; 2(2):116-26. DOI: 10.1038/nri727. View